COVID-19 Clinical Trial
— PCOV-19Official title:
A Prevalence Study of Persistent COVID-19 in Punta Arenas, Magallanes and Chilean Antarctic Region
This cross-sectional observational study aims to determine the prevalence of Persistent COVID-19 in 282 individuals in Punta Arenas, Magallanes and Chilean Antarctic Region. Persistent COVID-19 is a complex array of symptoms that persist or emerge for more than 4 weeks beyond SARS-CoV-2 infection. Recent studies suggest that up to 80% of survivors may develop chronic multi-organ dysfunction due to persistent inflammation and immune dysregulation, making it an ongoing public health concern worldwide. The study aims to (1) describe and establish the frequency of physical and psychological signs and symptoms in adult patients who have tested positive for COVID-19, (2) identify individuals who meet the WHO case definition of Persistent COVID-19 in Chile, (3) explore risk factors associated with persistent COVID-19 to guide intervention strategies, and (4) explore inflammatory and molecular biomarkers associated with persistent COVID-19. The research project utilizes a stratified random sampling with a mixed-methods embedded design. In the first phase, individuals diagnosed with COVID-19 will be recruited and followed up to complete the study's sample universe. A sociodemographic survey, blood sampling (including complete blood count, biochemical profile, immunoglobulin mutational status analysis, and analysis of inflammatory biomarkers), and a battery of psychological tests will be administered. In the second phase, kinesiology studies and medical consultation and evaluation will be conducted to determine if individuals have Persistent COVID-19 and to derive them to the healthcare network. In the final follow-up phase, participants diagnosed with Persistent COVID-19 will be invited to undergo musculoskeletal and respiratory assessments to complete the diagnosis of symptoms associated with the pathology.
Status | Recruiting |
Enrollment | 282 |
Est. completion date | January 15, 2025 |
Est. primary completion date | December 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | Inclusion Criteria: - Age = 18 years - Individuals must be included in the COVID-19 monitoring database by the SEREMI of Health in Punta Arenas between July 2022 and July 2023. - Patients able to give informed consent. Exclusion Criteria: - Age < 18 years - Any physical, mental, immunosuppressive, or social condition that, in the investigator's judgment, might interfere with the completion of the baseline assessments and evaluations. - Individuals who are digitally illiterate and do not have access to nearby networks to support them during the process. |
Country | Name | City | State |
---|---|---|---|
Chile | Teaching and Research Healthcare Center of the University of Magallanes (CADI-UMAG) | Punta Arenas | Magllanes And Chilean Antartic Region |
Lead Sponsor | Collaborator |
---|---|
Universidad de Magallanes | Centro Asistencial Docente e Investigación de la Universidad Magallanes (CADI-UMAG), Universidad de Santiago de Chile, University of Chile |
Chile,
Alvarado-Aravena C, Arriaza K, Castillo-Aguilar M, Flores K, Dagnino-Subiabre A, Estrada-Goic C, Nunez-Espinosa C. Effect of Confinement on Anxiety Symptoms and Sleep Quality during the COVID-19 Pandemic. Behav Sci (Basel). 2022 Oct 17;12(10):398. doi: 10 — View Citation
Gonzalez-Puelma J, Aldridge J, Montes de Oca M, Pinto M, Uribe-Paredes R, Fernandez-Goycoolea J, Alvarez-Saravia D, Alvarez H, Encina G, Weitzel T, Munoz R, Olivera-Nappa A, Pantano S, Navarrete MA. Mutation in a SARS-CoV-2 Haplotype from Sub-Antarctic Ch — View Citation
Sarmiento Varon L, Gonzalez-Puelma J, Medina-Ortiz D, Aldridge J, Alvarez-Saravia D, Uribe-Paredes R, Navarrete MA. The role of machine learning in health policies during the COVID-19 pandemic and in long COVID management. Front Public Health. 2023 Apr 11 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Musculoskeletal Capacity | Heart Rate Variability (HRV) analysis | 2 months | |
Other | Musculoskeletal Capacity | walk test (distance): 3D temporal scanning system for gait analysis by photogrammetry | 2 months | |
Other | Musculoskeletal Capacity | Postural Stability and Control Assessment Using Balance Tests | 2 months | |
Other | Respiratory function: | Spirometry: measurement of respiratory flows and volumes. | 2 months | |
Primary | To determine the prevalence of persistent COVID-19 in a cohort of patients in Punta Arenas | 13 months | ||
Secondary | Sociodemographic data questionnaire | to determine the number of prior illnesses, medical treatments, and vaccination records, as well as the quality of life scales, persistent COVID-19 symptoms through self-reported survey data, and Informed Consent Comprehension Questionnaire. | 3 months | |
Secondary | Psychological profiles | Beck Anxiety Scale (BAI) | 3 months | |
Secondary | Psychological profiles | D2-R test of attention | 3 months | |
Secondary | Psychological profiles | Wechsler Adult Intelligence Scale (WAIS) | 3 months | |
Secondary | Sleep quality and disorders | Pittsburgh Sleep Quality Index (PSQI) | 3 months | |
Secondary | Psychosocial exposures | COVID-19 related stress questionnaire based on the Perceived Stress Scale | 3 months | |
Secondary | Psychosocial exposures | Normal activities and work productivity questionnaire; daily diaries | 3 months | |
Secondary | Standard laboratory parameters | Full blood count | 3 months | |
Secondary | Standard laboratory parameters | Serum chemistry test | 3 months | |
Secondary | Inflammatory Biomarkers | Interleukin-8 (IL-8) | 6 months | |
Secondary | Inflammatory Biomarkers | Interleukin-1ß (IL-1ß) | 6 months | |
Secondary | Inflammatory Biomarkers | Interleukin-6 (IL-6) | 6 months | |
Secondary | Inflammatory Biomarkers | Interleukin-10 (IL-10) | 6 months | |
Secondary | Inflammatory Biomarkers | Tumor Necrosis Factor (TNF) | 6 months | |
Secondary | Inflammatory Biomarkers | Interleukin-12 (IL-12p70) | 6 months | |
Secondary | Immunological repertoire associated with persistent COVID-19 | DNA sequencing results | 6 months | |
Secondary | Flow Cytometry Immunophenotyping | Quantify different lymphocyte subpopulations in persistent COVID-19 | 6 months | |
Secondary | Flow Cytometry Immunophenotyping | Quantify Age-Associated B Cells and Their Potential Role in Persistent COVID-19 Pathogenesis | 6 months | |
Secondary | Function of the musculoskeletal system | Fatigue Assessment Scale (FAS) | 6 months | |
Secondary | Function of the musculoskeletal system | Body Composition Analysis Assessment | 6 months | |
Secondary | Function of the musculoskeletal system | Hand Grip Strength Test | 6 months | |
Secondary | Function of the musculoskeletal system | Maximum inspiratory pressure test (MIP test) | 6 months | |
Secondary | Diagnosis of prevalent COVID-19 | Clinical determination of whether the patient has persistent COVID-19 or not is necessary for referral to the appropriate healthcare system | 8 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|